Business
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the
About this update from Invivyd, Inc.
[{"type":"text","content":"Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of measlesMeasles (rubeola) virus appears to offer an attractive target for best-in-class monoclonal antibody discovery and development utilizing Invivyd technologyMore than 20 million Americans are unvaccinated against measles; U.S. is at risk for losing functional elimination as vaccination rates declineGoal is to identify a preclinical measles mAb candidate in 2025; company anticipates providing a progress update by end of year WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles and monitoring contacts and outbreaks have inquired directly to Invivyd about the possibility of accessing such a medicine, as there are no currently approved therapies for measles or for post-exposure prophylaxis. Measles monoclonal neutralizing antibody discovery efforts would join current Invivyd discovery programs for next-generation COVID-19, respiratory syncytial virus (RSV), and influenza mAbs designed to treat acute infection or provide a high-quality alternative to vaccination. There are currently no anti-viral treatments for measles. Clinicians have limited options for treatment of individuals sick with measles including high-dose Vitamin A, which is useful to support recovery from measles infections among children who are Vitamin A deficient, and human donor-derived pooled plasma immune globulin (IG) administered via IV (IVIG) to treat active phase measles. Both therapies have limitations for treatment, in addition to not being approved, well-characterized clinical tools: Vitamin A can be hepatotoxic, and IVIG is a non-uniform, polyclonal collection of antibodies collected and pooled from many donors and is poorly suited for widespread use. Standard measles vaccines confer excellent, long-lasting protection from disease and are the most important tools to prevent measles infection but have important limitations in post-exposure prophylaxis and are increasingly underutilized by sizeable populations in Americ...